Efficacy, pharmacokinetics, and safety of Trogarzo Good to see more recognition of Trogarzo’s efficacy/safety on a well credited journal.
“In this highly treatment-experienced population, ibalizumab administered q2wk at 15 mg/kg or at 10 mg/kg (with weekly dosing during the 9-week loading period) was safe and well tolerated and resulted in sustained antiviral and immunological response over 48 weeks. With proven activity against multiple drug-resistant strains regardless of viral tropism, ibalizumab is a valuable addition to the treatment armamentarium. Because of its effective inhibition of HIV entry, tolerability, and long-acting dosing, ibalizumab is an attractive drug for use in individuals with limited treatment options because of multidrug resistance.”
https://journals.lww.com/jaids/Fulltext/2021/04010/Efficacy,_Pharmacokinetics,_and_Safety_Over_48.16.aspx